F

acing a huge debt, pricing pressures, and various missteps, the new Teva Pharmaceutical (TEVA) chief executive on Monday overhauled his management team and reorganized key business units in a Hail Mary bid to revive the beleaguered drug maker.

Underscoring the severity of the situation, those exiting at the end of next month include three key executives: R&D chief Michael Hayden; Rob Koremans, who headed the global specialty medicines group; and Dipankar Bhattacharjee, who ran the global generic drug business.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X